Abstract

Nuclear factor-kappaB (NF-kappaB)-based signaling regulates diverse biological processes, and its deregulation is associated with various disorders including autoimmune diseases and cancer. Identification of novel factors that modulate NF-kappaB function is therefore of significant importance. The Mastermind-like 1 (MAML1) transcriptional co-activator regulates transcriptional activity in the Notch pathway and is emerging as a co-activator of other pathways. In this study, we found that MAML1 regulates NF-kappaB signaling via two mechanisms. First, MAML1 co-activates the NF-kappaB subunit RelA (p65) in NF-kappaB-dependent transcription. Second, MAML1 causes degradation of the inhibitor of NF-kappaB (IkappaBalpha). Maml1-deficient mouse embryonic fibroblasts showed impaired tumor necrosis factor-alpha (TNFalpha)-induced NF-kappaB responses. Moreover, MAML1 expression level directly influences cellular sensitivity to TNFalpha-induced cytotoxicity. In vivo, mice deficient in the Maml1 gene exhibited spontaneous cell death in the liver, with a large increase in the number of apoptotic hepatic cells. These findings indicate that MAML1 is a novel modulator for NF-kappaB signaling and regulates cellular survival.

Highlights

  • Nuclear factor-␬B (NF-␬B) consists of homo- or heterodimers of members of the Rel family: RelA (p65), RelB, c-Rel, p105 and its processing product p50, and p100 and its processing product p52

  • We found that effectively; both domains WT mouse embryonic fibroblasts (MEFs) showed dose-dependent activation of the are required for Mastermind-like 1 (MAML1) to regulate I␬B␣ expression

  • We further showed that the expression of human modification of its interacting proteins and I␬B␣ undergoes MAML1 in Maml1-ko MEFs enhanced the overall NF-␬B sigphosphorylation for subsequent ubiquitination and degrada- naling but not up to the level that exhibited by WT MEFs

Read more

Summary

Introduction

NF-␬B consists of homo- or heterodimers of members of the Rel family: RelA (p65), RelB, c-Rel, p105 and its processing product p50, and p100 and its processing product p52. When cells were treated with MG132, I␬B␣ expression was not significantly reduced by MAML1 compared with DMSO treatment (compare lane 8 with lane 3 in Fig. 4E), indicating that MAML1-induced

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call